Get the Stockscreener App
16.31
0.00%
0.00
After Hours:
16.31
Rallybio Corp stock is traded at $16.31, with a volume of 16,069.
It is up +0.00% in the last 24 hours and up +1.94% over the past month.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
See More
Previous Close:
$16.31
Open:
$16.47
24h Volume:
16,069
Relative Volume:
0.07
Market Cap:
$86.56M
Revenue:
$858.00K
Net Income/Loss:
$-7.82M
P/E Ratio:
-11.25
EPS:
-1.4503
Net Cash Flow:
$-27.59M
1W Performance:
-2.39%
1M Performance:
+1.94%
6M Performance:
+218.50%
1Y Performance:
+308.81%
1-Day Range:
$16.06
$16.48
1-Week Range:
$16.00
$16.98
52-Week Range:
$3.20
$17.57
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
16.31 | 86.56M | 858.00K | -7.82M | -27.59M | -1.4503 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
RLYB|Rallybio Corp|Price:16.310|Chg%:-0.080 - TradingKey
Rallybio Market Sentiment - Benzinga España
Rallybio Corp (RLYB) Institutional Confidence - TradingKey
Rallybio Corporation Revenue Breakdown – FWB:33M0 - TradingView
Rallybio Corporation Revenue Breakdown – TRADEGATE:33M0 - TradingView
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Stocktwits
Rallybio Corp (RLYB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rallybio Corporation (NASDAQ: RLYB) to merge and rebrand as Avenzo Therapeutics - Stock Titan
Total assets of Rallybio Corporation – FWB:33M0 - TradingView
Price to earnings forward of Rallybio Corporation – NASDAQ:RLYB - TradingView
Enterprise value to revenue forward of Rallybio Corporation – NASDAQ:RLYB - TradingView
Book value per share of Rallybio Corporation – FWB:33M0 - TradingView
Price to book forward of Rallybio Corporation – FWB:33M0 - TradingView
Long term debt to total equity ratio of Rallybio Corporation – FWB:33M0 - TradingView
Price to sales forward of Rallybio Corporation – FWB:33M0 - TradingView
Enterprise value to EBITDA forward of Rallybio Corporation – FWB:33M0 - TradingView
Net income before discontinued operations of Rallybio Corporation – FWB:33M0 - TradingView
Rallybio Corporation (RLYB) Edges Lower Amid Consolidation Near SupportLong Term Entry Picks - dars.gov.et
Rallybio Corp (RLYB) director exercises stock options, lifts stake to 6,542 shares - Stock Titan
Rallybio Corporation (RLYB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Rallybio (RLYB) Drifts Marginally Lower, Consolidating Between Key Support and ResistanceTrade Entry Signals - DonanımHaber
Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock By Investing.com - Investing.com Nigeria
Rallybio Company Profile & Introduction - Moomoo
Rallybio Corporation(NasdaqCM: RLYB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rallybio Corporation(NasdaqCM: RLYB) added to Russell Microcap Index - marketscreener.com
Rallybio Corporation(NasdaqCM: RLYB) added to Russell 3000E Index - marketscreener.com
RLYB stock hits 2-year highs after unveiling merger with Avenzo – how much of the new company will Rallybio shareholders own? - MSN
What's Driving Rallybio's Recent Surge and Investor Interest - Kavout | AI
Rallybio Corporation Actuals & Estimates (NASDAQ:RLYB) - TradingView
Rallybio Corporation (RLYB) Shows Modest Uptick, Testing Key Resistance LevelsLate Stage Breakouts - dars.gov.et
Rallybio Corp (RLYB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rallybio Corp (RLYB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rallybio Corp (RLYB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rallybio Corp (RLYB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rallybio Corp (RLYB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rallybio Corp (RLYB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RLYB Q1 2026 Earnings: Wider-Than-Expected Loss Underscores Pre-Revenue StageEarnings Call Q&A - dars.gov.et
Rallybio to Acquire Avenzo Therapeutics and Complete $215 Million Private Placement - Global Legal Chronicle
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
JOHNSON & JOHNSON's Rallybio Corp(RLYB) Holding History - GuruFocus
San Diego Biotech Upstart Avenzo Plots Nasdaq Splash In Rallybio Reverse Merger - Hoodline
United StatesMintz Advising On $215 Million Private Placement Concurrent With Avenzo Therapeutics’ And Rallybio’s Merger Transaction - Mondaq
Avenzo Picks Up Reverse Merger Ditched by Candid - San Diego Business Journal
ADAR1, Daniel Schneeberger disclose 17.5% stake in Rallybio (RLYB) - Stock Titan
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):